Although atypical antipsychotics have become the standard of care for the management of psychosis associated with dementia, adverse effect profiles remain a concern in this sensitive population. Furthermore, controlled efficacy data in elderly patients is limited and data from primary psychotic disorders are often used to predict benefits for psychosis associated with dementia. Aripiprazole is a novel atypical antipsychotic agent with a unique mechanism of action. Data from schizophrenia and bipolar mania trials demonstrate strong antipsychotic efficacy with an early onset of action and a favorable adverse effect profile. A controlled trial in patients with psychosis associated with AD adds direct evidence for efficacy in geriatric patients.
Back to S103 Effective Management of Patients with Dementia and Psychotic Symptoms
Back to Satellite Symposia
Back to The Eleventh International Congress